MedImmune Limited, a subsidiary of AstraZeneca PLC, and Celgene International II Sà rl, a subsidiary of Celgene Corporation, have formed a strategic collaboration for the development and commercialization of AstraZeneca’s anti-programmed cell death-ligand 1 (PD-L1) agent MEDI4736.
